On Thursday, Shares of NVIDIA Corporation (NASDAQ:NVDA), lost -0.63% to $20.45.
NVIDIA, stated revenue for the second quarter ended July 26, 2015, of $1.153 billion, up 5 percent from $1.103 billion a year earlier, and up marginally from $1.151 billion the previous quarter.
GAAP earnings per diluted share for the quarter were $0.05. This comprises a charge of $0.19 per diluted share in connection with the company’s decision to wind down its Icera® modem operations, after a viable buyer failed to emerge. It also comprises a charge of $0.02 per diluted share related to the NVIDIA SHIELD™ tablet recall.
NVIDIA Corporation operates as a visual computing company in the United States, Taiwan, China, the rest of Asia Pacific, Europe, and other Americas. The company operates through two segments, GPU and Tegra Processors.
Shares of Calpine Corporation (NYSE:CPN), inclined 0.46% to $17.29, during its last trading session.
The Environmental Protection Agency’s release of the Clean Power Plan represents a seminal moment for the power generation industry. Based on statements by President Obama and the EPA, it appears the plan mandates noteworthy but achievable CO2 emissions reductions while giving the states broad discretion in how to achieve those aims. Specifically, the plan provides a framework that will allow states to adopt a market-based approach to achieving reductions, easing the states’ burden while allowing market economics to decide the best mix of generation resources to achieve the aim. Importantly, these emissions reductions will be realized in a manner that ensures continued affordable and reliable electricity. Calpine Corporation (CPN) believes the plan, as broadly described, is a workable and achievable approach to control CO2 emissions that will benefit generations to come.
“The Clean Power Plan represents a commitment to ongoing the transition from carbon-intensive generation to efficient, low-carbon generation,” said Thad Hill, President and Chief Executive Officer of Calpine. “This flexible, market-based solution will reward the companies that invest and have invested smartly in cleaner generation. We applaud the EPA for its efforts throughout this collaborative process and look forward to working with the agency, states and other stakeholders as the rule is ultimately implemented.”
Calpine Corporation, a wholesale power generation company, owns and operates natural gas-fired and geothermal power plants in North America. It operates natural gas-fired combustion turbines and renewable geothermal conventional steam turbines.
Finally, CytRx Corporation (NASDAQ:CYTR), ended its last trade with -3.05% loss, and closed at $2.54.
CytRx Corporation stated financial results for the three months ended June 30, 2015, and also offered an overview of recent accomplishments and forthcoming milestones for its clinical development programs.
“The second quarter of 2015 has been very productive for CytRx. Enrollment in our ongoing pivotal global Phase 3 clinical trial of aldoxorubicin in soft tissue sarcoma (STS) continues on track to be accomplished in the first quarter of 2016. On the financial front, we successfully closed a public equity offering raising an additional $28.8 million in gross proceeds, which significantly strengthens our balance sheet and allows us to further advance the aldoxorubicin program, provide for pre-commercialization launch expenses, and introduce our next generation of therapies into the clinic in 2016,” said Steven A. Kriegsman, Chairman and CEO of CytRx. “The second quarter also comprised of the declaration of promising updated data from our Phase 2 programs evaluating aldoxorubicin in Kaposi’s Sarcoma (KS) and glioblastoma (GBM), in addition to compelling data in our two combination trials.”
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with soft tissue sarcoma; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
